Results 1 to 10 of about 1,418,684 (317)

Acknowledgment to the Reviewers of Current Oncology in 2022

Current Oncology, 2023
High-quality academic publishing is built on rigorous peer review [...]
Current Oncology Editorial Office
doaj   +1 more source

Acknowledgment to Reviewers of Current Oncology in 2021

Current Oncology, 2022
Rigorous peer-reviews are the basis of high-quality academic publishing [...]
Current Oncology Editorial Office
doaj   +1 more source

Integrative Oncology [PDF]

Evidence-Based Complementary and Alternative Medicine, 2013
OA ...
Gustav Dobos, Holger Cramer, Shrikant Anant, Claudia M. Witt, Lorenzo Cohen   +4 more
openaire   +3 more sources

Oncology

Current Pharmaceutical Design, 2021

openaire   +2 more sources

Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors

Xiehe Yixue Zazhi, 2021
Immune checkpoint inhibitors (ICI) have shown efficacy for some patients with gynecological tumors, which are mainly used to treat persistent, recurrent, or metastatic patients.
Gynecological Oncology Society of Chinese Medical Association
doaj   +1 more source

Expert Consensus on Management of Common Gynecological Malignancies Combining General Practice and Specialist [PDF]

Zhongguo quanke yixue
To enhance the overall health management for patients with gynecologic malignant tumors, and to fully leverage the role of primary healthcare institutions in screening and rehabilitation, the Gynecological Oncology Group of the Oncology Department of ...
Gynecological Oncology Group of the Oncology Department of Capital Medical University
doaj   +1 more source

Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

Current Therapeutic Research, 2022
: Background: CRC is the second and third most common cancer in women and men, respectively. The national comprehensive cancer network guidelines recommend oxaliplatin-based chemotherapy as a preferred regimen for patients with advanced or metastatic ...
Farhad Shahi, Mojtaba Gorji, Assistant Professor of Pediatric Oncology, Mehrdad Payandeh, Assistant Professor of Hematology & Oncology, Hamid Rezvani, Associate Professor of Hematology & Oncology, Mohammad Vaezi, Associate Professor of Hematology & Oncology, Sharareh Seifi, Assistant Professor of Hematology & Oncology, Alireza Baari, Post doctoral fellowship, Reza Khalili-Dizaji, Post doctoral fellowship, Seyed Mehdi Hashemi, Associate Professor of Hematology & Oncology, Saeid Salimi, post doctoral fellowship, Hosein Kamranzadeh, Associate Professor of Hematology & Oncology, Babak Shazad, Post doctoral fellowship, Sina Salari, Associate Professor of Hematology & Oncology, Davoud Oulad Dameshghi, Assistant Professor of Hematology & Oncology, Mehdi Sarkheil, Post doctoral fellowship, Mehrzad Mirzania, Associate Professor of Hematology & Oncology, Nassim Anjidani, Pharm. D.   +16 more
doaj   +1 more source

Expert consensus on early diagnosis and treatment of bladder cancer (2024 edition) [PDF]

Zhongguo aizheng zazhi
Bladder cancer is one of the common cancers of urinary system, which seriously threatens the life and health of Chinese population. In recent years, with the extension of life expectancy and the acceleration of aging, the incidence and mortality rates of
Urologic Chinese Oncology Group
doaj   +1 more source

Oncologic emergencies [PDF]

Vnitřní lékařství, 2019
Oncologic emergencies and life-threatening cancer-related and treatment-related complications are the net effect of gradually increasing incidence of malignant diseases, improvement of therapeutic options and survival of oncologic patients. These complications are relatively specific for such population of patients and they are quite rare within the ...
Thomas, Karvuni, Martin, Matějovič
openaire   +2 more sources

Adjuvant chemotherapy non‐adherence, patient‐centered communication, and patient‐level factors in elderly breast and colon cancer patients

Cancer Medicine, 2023
Background We examined patient‐level factors (patient characteristics, disease and treatment factors, and patient experience), patient‐centered communication (PCCM), and non‐adherence to adjuvant chemotherapy (AC) guidelines among breast and colon cancer
Kerri‐Anne R. Mitchell, Joseph R. Boyle, Lenka Juricekova, Richard F. Brown   +3 more
doaj   +1 more source